http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-923904-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d629f98a51b15993f56f9e04fdea237f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J75-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
| filingDate | 1959-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1963-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-923904-A |
| titleOfInvention | Novel androstane derivatives and process for their manufacture |
| abstract | The invention comprises steroids of the formula <FORM:0923904/IV(a)/1> (wherein the 1,2-double bond is optional, X is hydrogen, fluorine, chlorine or bromine, Y is keto or H(b OH) or together with X is an additional 9(11)-bond or a 9b ,11b -oxido group, and Z is keto, H(b OH) or esterified H(b OH)) and their preparation by submitting a steroid of the formula <FORM:0923904/IV(a)/2> (wherein X1 and Y1 have the same significance as X and Y respectively, and Z1 is an ethyl radical bearing an oxygen function in the 20-position or 20- and 21-positions), to degrading oxidation to form the corresponding 17-keto compound followed, if required, by (a) reduction to the 17-ol and, if desired, esterification of the latter; (b) hydrogenation or dehydrogenation in the 1,2-position; (c) reduction of 11-keto to 11a - or 11b -hydroxy; (d) one or more of the processes of dehydration, addition of hypohalogenous acid, dehydrohalogenation, and epoxide scission by means of hydrogen halide, of or to the 9H,11-hydroxy, 9(11)-ene, 9b ,11b -oxido or 9a -halogeno-11b -hydroxy compound, to form another of these compounds except the first; and (e) oxidation of 11-hydroxy to 11-keto. Degradation of the side chain may be effected with sodium bismuthate, chromic acid, periodic acid or lead tetraacetate, for example, although the use of strong oxidizing agents such as chromium trioxide also results in oxidation of 11b -hydroxy to 11-keto. Introduction of a D 1-double bond may be affected microbiologically or chemically, e.g. with selenium dioxide or the use of bromine followed by dehydrobromination. Reduction of the 17-ketones to the 17-ols may be effected with Saccharomyces cerevisiae, or chemically with a metal hydride. 11-Alcohols may be converted to D 9(11)-compounds by conversion to sulphonic esters followed by elimination of the elements of the particular sulphonic acid, a 21-hydroxy group, if present, being protected by esterification. 11-Ketones may be reduced to 11-ols by standard procedures, other keto groups being protected by ketal formation, and 11-ols may be oxidized to 11-ketones with, for example, chromic acid. Detailed examples are provided, and esters with acetic, propionic, butyric, trimethyl-acetic, t-buyl-acetic, phosphoric, succinic and sulphobenzoic acids, and sodium salts thereof, are also referred to. 9a -Chloro- and bromo-16a -methyl-prednisolones are prepared by dehydrogenation of 9a -chloro- and bromo-16a -methyl-hydrocortisones with Corynebacterium simplex. 16a -Methyl-4,9-(11)-pregnadiene-17a ,21-diol-3, 20-dione-21-acetate is prepared by dehydration of the corresponding 11a - or 11b -ol. The steroids of the invention, which are stated to be useful in the treatment of mental depression and to exhibit anti-inflammatory properties, may be made up into pharmaceutical compositions with suitable carriers. Tablets, elixirs, suspensions and solutions are mentioned. Specification 807,227 is referred to. |
| priorityDate | 1958-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.